UMIN-CTR Clinical Trial

BACK TOP
UMIN-CTR English Home Glossary (Simple) FAQ Search clinical trials

Name:
UMIN ID:

Recruitment status Completed
Unique ID issued by UMIN UMIN000015470
Receipt No. R000017984
Scientific Title Effect of metformin on the endometrium of obese, insulin-resistant women
Date of disclosure of the study information 2014/10/20
Last modified on 2019/04/23

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title Effect of metformin on the endometrium of obese, insulin-resistant women
Acronym Effect of metformin on the endometrium of obese, insulin-resistant women
Scientific Title Effect of metformin on the endometrium of obese, insulin-resistant women
Scientific Title:Acronym Effect of metformin on the endometrium of obese, insulin-resistant women
Region
Japan

Condition
Condition obese, insulin-resistant women
Classification by specialty
Obsterics and gynecology
Classification by malignancy Others
Genomic information NO

Objectives
Narrative objectives1 This study will investigate the antiproliferative effects of metformin on the endometrium of obese, insulin-resistant women. The changes in serum levels of insulin, insulin-like growth factor-1 (IGF-1), adipocytokines (leptin and adiponectin); body mass index (BMI); and insulin resistance will be evaluated after metformin intake.
Basic objectives2 Efficacy
Basic objectives -Others
Trial characteristics_1 Exploratory
Trial characteristics_2 Others
Developmental phase Not applicable

Assessment
Primary outcomes To evaluate the effect of metformin on phospho-ERK expression in the endometrium
Key secondary outcomes 1. To evaluate the effect of metformin on biomarker expression in the endometrium. Differences in Ki-67 and topoisomeraseIIa; expression will be assessed immunohistochemically.Phospho-AKT, phospho-AMPK, phospho-rpS6, cyclin D1, pRB, and p27 will be assessed using western blot analysis.
2. To evaluate the effect of metformin on serum biomarkers, such as insulin, IGF-1, and adipocytokines, such as leptin and adiponectin.
3. To evaluate the changes in BMI and insulin resistance after metformin treatment.
4. To evaluate the changes in the growth-stimulatory potential of sera after metformin treatment.



Base
Study type Interventional

Study design
Basic design Single arm
Randomization Non-randomized
Randomization unit
Blinding Open -no one is blinded
Control Uncontrolled
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms 1
Purpose of intervention Prevention
Type of intervention
Medicine
Interventions/Control_1 1) Patients will receive a daily dose of metformin (initial dose, 500 mg/day; increasing, weekly, up to 1500 mg/day, in the absence of adverse effects) for 3 months
2) Blood samples and endometrial biopsies will be obtained at baseline and after 3 months.
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
20 years-old <=
Age-upper limit
45 years-old >=
Gender Female
Key inclusion criteria 1. Normal endometrium or simple hyperplasia, without atypia.
2. BMI 25 and over and a positive test for insulin resistance
3. Menstrual irregularity
4. Aged between 20- and 45-years-old
5. Eastern Cooperative Oncology Group Performance status 0
6. Provided written informed consent
Key exclusion criteria 1. Prior medical history of chemical sensitivity to metformin
2. Women desiring to become pregnant during the study period
3. Serum creatinine level >1.0 mg/dL
4. History of lactic acidosis
5. Requiring dialysis
6. Shock, cardiac arrest, cardiac infarction, pulmonary thrombosis, or severe cardiovascular and/or lung damage
7. Ingestion of excessive amounts of alcohol
8. Liver dysfunction
9. History of thrombosis
10. Mental illness that may require antipsychotic therapy
11. Diabetes mellitus requiring medication
12. Concomitant malignancies
13. Ineligible, as determined by the physician-in-charge for any other reason
Target sample size 15

Research contact person
Name of lead principal investigator
1st name AKIRA
Middle name
Last name Mitsuhashi
Organization Graduate School of Medicine, Chiba University,
Division name Reproductive Medicine
Zip code 260-8670
Address 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan
TEL 043-222-7171
Email antira@faculty.chiba-u.jp

Public contact
Name of contact person
1st name AKIRA
Middle name
Last name Mitsuhashi
Organization Graduate School of Medicine, Chiba University
Division name Reproductive Medicine
Zip code 260-8670
Address 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan
TEL 043-222-7171
Homepage URL
Email antira@faculty.chbia-u.jp

Sponsor
Institute Graduate School of Medicine, Chiba University
Institute
Department

Funding Source
Organization The Japan Society for Promotion
of Science
Organization
Division
Category of Funding Organization Japanese Governmental office
Nationality of Funding Organization

Other related organizations
Co-sponsor
Name of secondary funder(s)

IRB Contact (For public release)
Organization Chiba University Hospital
Address 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan
Tel 043-222-7171
Email hanaoka.hideki@faculty.chiba-u.jp

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions

Other administrative information
Date of disclosure of the study information
2014 Year 10 Month 20 Day

Related information
URL releasing protocol
Publication of results Unpublished

Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status Completed
Date of protocol fixation
2014 Year 10 Month 14 Day
Date of IRB
2014 Year 10 Month 14 Day
Anticipated trial start date
2014 Year 10 Month 20 Day
Last follow-up date
2019 Year 03 Month 31 Day
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Other
Other related information

Management information
Registered date
2014 Year 10 Month 19 Day
Last modified on
2019 Year 04 Month 23 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000017984

Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name


Contact us.